A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB(4) receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

BACKGROUND: Airway inflammation, mediated in part by LTB(4), contributes to lung destruction in patients with cystic fibrosis (CF). LTB(4)-receptor inhibition may reduce airway inflammation. We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safety of t...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Cyst Fibros
Autores principales: Konstan, MW, Döring, G, Heltshe, SL, Lands, LC, Hilliard, KA, Koker, P, Bhattacharya, S, Staab, A, Hamilton, A
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4755340/
https://ncbi.nlm.nih.gov/pubmed/24440167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2013.12.009
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares